Seeking Alpha

Chelsea Therapeutics (CHTP) craters in spite of announcing positive preliminary results for...

Chelsea Therapeutics (CHTP) craters in spite of announcing positive preliminary results for Study 306B, a Phase III trial of Northera, a treatment for hypotension associated with Parkinson's Disease, saying the trial met its primary endpoint. The devil lies in the details however, as investors react to the results under the shadow of the FDA's earlier statement that the trial was unlikely to provide sufficient confirmatory evidence to support an NDA. Shares -22% AH.
Comments (2)
  • Yikes! Just when I thought the end was near for CHTP... well the end may be near... just not the ending I was expecting!
    4 Dec 2012, 06:47 PM Reply Like
  • Could the Reaction from investors be Wrong???
    We will Find Out! But maybe I don't let stock stick Around to find out!
    What a bummer! was such a good stock!
    5 Dec 2012, 12:07 AM Reply Like
DJIA (DIA) S&P 500 (SPY)